A recent study has unveiled a concerning link between semaglutide, the active ingredient in Novo Nordisk’s popular medications Ozempic and Wegovy, and a rare eye condition that can lead to blindness. Published in the journal JAMA Ophthalmology, the research conducted by Harvard scientists found that patients prescribed semaglutide were significantly more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION) than those on other weight loss drugs. This eye condition, which affects only about 10 out of every 100,000 people, blocks blood flow to the optic nerve, potentially resulting in irreversible blindness. Alarmingly, there is currently no known treatment for NAION.
The study examined a mix of patients with type 2 diabetes and those who were simply overweight. Out of 710 patients with type 2 diabetes, 194 had been prescribed semaglutide. Within this group, there were 17 reported cases of NAION, compared to just six cases among those prescribed other diabetes medications. This translates to 8.9 percent of the semaglutide group experiencing NAION events, a stark contrast to the 1.8 percent observed in the other cohort.
For the overweight subjects, the statistics were even grimmer. Among 975 patients, 361 were prescribed semaglutide, and within this subgroup, 20 experienced NAION events over a three-year period. In comparison, among the remaining 614 patients who took other weight loss drugs, only three reported NAION events. Essentially, the study revealed that overweight patients on semaglutide were more than seven times as likely to develop NAION compared to those on other medications. Overall, 6.7 percent of those on semaglutide had NAION events, compared to just 0.8 percent for those on other weight loss drugs.
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, responded to the findings in a statement to The Guardian. The company emphasized that it takes all reports of adverse events seriously but noted that NAION is not listed as a known adverse drug reaction in the official product documentation. This response, however, might do little to assuage the growing concerns over the drug’s safety profile.
The implications of this study are particularly troubling given the increasing popularity and usage of semaglutide. While the drug is currently approved for treating type 2 diabetes and obesity, it’s also being considered for other medical conditions. This raises the stakes for further research and scrutiny, as experts like Queen’s University Belfast physiology professor Graham McGeown have pointed out. According to McGeown, the potential adverse side effects of semaglutide must be weighed carefully against its benefits, especially given its expanding use.
As the medical community grapples with these findings, patients and healthcare providers are left in a precarious position. The promise of effective weight loss and diabetes management must now be balanced against the alarming risk of a devastating eye condition. This study serves as a crucial reminder of the importance of comprehensive research and vigilance in the rapidly evolving landscape of pharmaceutical advancements.
By
